Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models

Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models

Abstract Background Doxorubicin (DXR) hydrochloride (HCl) liposome injection is an important part of the treatment armamentarium for a number of cancers. With growing needs for affordable and effective anticancer treatments, the development of generics is becoming increasingly important to facilitat...

Full description

Bibliographic Details
Main Authors: Vinod Burade, Subhas Bhowmick, Kuntal Maiti, Rishit Zalawadia, Harry Ruan, Rajamannar Thennati
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Anthracycline
Bioequivalence
Doxorubicin HCl liposome injection
In vivo
Preclinical
Online Access:http://link.springer.com/article/10.1186/s12885-017-3377-3

Internet

http://link.springer.com/article/10.1186/s12885-017-3377-3

Similar Items